Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-cash Items (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Non-cash Items for 11 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 63.86% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 63.86% year-over-year, with the annual reading at $1.3 million for FY2025, 63.86% down from the prior year.
  • Non-cash Items hit $1.3 million in Q4 2025 for Voyager Therapeutics, down from $3.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $17.9 million in Q1 2024 to a low of $1.2 million in Q4 2021.
  • Historically, Non-cash Items has averaged $5.1 million across 5 years, with a median of $3.6 million in 2021.
  • Biggest five-year swings in Non-cash Items: soared 709.58% in 2021 and later crashed 71.66% in 2025.
  • Year by year, Non-cash Items stood at $1.2 million in 2021, then surged by 423.18% to $6.1 million in 2022, then surged by 85.28% to $11.3 million in 2023, then crashed by 69.34% to $3.5 million in 2024, then tumbled by 63.86% to $1.3 million in 2025.
  • Business Quant data shows Non-cash Items for VYGR at $1.3 million in Q4 2025, $3.1 million in Q3 2025, and $5.7 million in Q2 2025.